PTC Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

• PTC Therapeutics Inc PTCT.OQ reported a quarterly adjusted loss of 83 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-1.27. The mean expectation of seventeen analysts for the quarter was for a loss of 21 cents per share. Wall Street expected results to range from $-1.77 to -37 cents per share.

• Revenue fell 4.2% to $1.18 billion from a year ago; analysts expected $168.25 million.

• PTC Therapeutics Inc's reported EPS for the quarter was $10.04​.

• The company reported a quarterly loss of $64.85 million.

• PTC Therapeutics Inc shares had risen by 5.2% this quarter and gained 13.8% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 78.7% in the last three months.​

• In the last 30 days, six analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," 5 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for PTC Therapeutics Inc is $64.00, about 21.3% above its last closing price of $50.36

This summary was machine generated from LSEG data August 8 at 03:02 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)